MDL | MFCD07369025 |
---|---|
Molecular Weight | 412.01 |
Molecular Formula | C20H26ClNO2S2 |
SMILES | O=C([C@H]1CN(CC/C=C(C2=C(C)C=CS2)/C3=C(C)C=CS3)CCC1)O.[H]Cl |
Tiagabine hydrochloride is a potent and selective GABA reuptake inhibitor, used as an anticonvulsant agent, with IC 50 s of 67, 446 and 182 nM for [ 3 H]GABA uptake in Synaptosomes, Neurons and Glia, respectively [1] .
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00086255 | National Institute on Drug Abuse (NIDA)|University of Cincinnati |
Cocaine-Related Disorders
|
October 2002 | Phase 2 |
NCT00179465 | Beth Israel Deaconess Medical Center|Dartmouth-Hitchcock Medical Center |
Schizophrenia
|
November 2003 | Phase 3 |
NCT00129298 | National Institute on Drug Abuse (NIDA) |
Cocaine-Related Disorders|Opiate Dependence
|
December 2004 | Phase 2 |
NCT02387710 | Brigham and Women´s Hospital |
Sleep Apnea, Obstructive
|
March 2015 | Phase 2 |
NCT03196466 | Assistance Publique - Hôpitaux de Paris |
Epilepsy
|
June 19, 2017 | |
NCT01904487 | Rajesh Narendran|University of Pittsburgh |
Alcoholism
|
April 19, 2011 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
H 2 O : 100 mg/mL ( 242.71 mM ; Need ultrasonic)
DMSO : ≥ 53 mg/mL ( 128.64 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.4271 mL | 12.1356 mL | 24.2713 mL |
5 mM | 0.4854 mL | 2.4271 mL | 4.8543 mL |
10 mM | 0.2427 mL | 1.2136 mL | 2.4271 mL |